IDIENCE CO., LTD.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.idience.com
Food Effect Study of IDX-1197 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Male
- Interventions
- Drug: IDX-1197(After a meal)Drug: IDX-1197(fasting)
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Idience Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT05202912
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
Phase 1
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- Drug: IDX-1197+XELOXDrug: IDX-1197+Irinotecan
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Idience Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT04725994
- Locations
- πΊπΈ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈAstera Cancer Care, East Brunswick, New Jersey, United States
π°π·Dong-A University Hospital, Busan, Korea, Republic of
Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)
Phase 1
Completed
- Conditions
- Solid TumorsHomologous Recombination Repair Gene MutationHomologous Recombination Deficiency
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Idience Co., Ltd.
- Target Recruit Count
- 310
- Registration Number
- NCT04174716
- Locations
- π°π·
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
π°π·National Cancer Centre, Goyang, Gyeongggi-do, Korea, Republic of
π°π·Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of
Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: NOV140101 (IDX-1197)
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Idience Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03317743
- Locations
- π°π·
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath